News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA OKs Expanded Label of Abbott Laboratories (ABT)'s Treatment for Premature Puberty


10/31/2011 8:35:36 AM

The US Food and Drug Administration (FDA) have approved Abbott’s supplemental New Drug Application (sNDA) for Lupron Depot-PED (leuprolide acetate for depot suspension). The one-month formulation is the first product in its class to include long-term data in its label for the treatment of central precocious puberty (CPP), a condition which causes children to enter puberty too soon. The prescribing information now contains 18 years of data, including pre-specified outcome results on puberty, height and reproductive function.

Read at PharmaBiz
Read at News Release
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES